These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Inhibition of microRNA-218 promotes oral squamous cell carcinoma growth by targeting GLUT1 to affect glucose metabolism.
    Author: Xu XJ, Yuan J, Sun WJ, Chen QY, Lin Y, Tang L, Liang LZ.
    Journal: Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7726-7734. PubMed ID: 30536316.
    Abstract:
    OBJECTIVE: Glucose transporter 1 (GLUT1) is a key player in glucose metabolism that has important roles in oral squamous cell carcinoma (OSCC), while microRNA-218 can target GLUT1 to achieve its biological roles. Therefore, we hypothesize that microRNA-218 may target GLUT1 to participate in OSCC. PATIENTS AND METHODS: Tumor tissues and adjacent healthy tissues were collected from OSCC patients, and blood samples were collected from both OSCC patients and healthy controls. Expression of microRNA-218 and GLUT1 in those tissues was detected by qRT-PCR. All patients were followed up for 5 years. Diagnostic and prognostic values of serum microRNA-218 for OSCC were investigated by ROC curve analysis and survival curve analysis, respectively. MicroRNA-218 knockdown OSCC cell lines were established. The effects on cell proliferation, glucose uptake as well as GLUT1 expression were detected by CCK-8 assay, glucose uptake assay and Western blot. RESULTS: MicroRNA-218 expression level was decreased while GLUT1 expression level was increased in tumor tissues compared with adjacent healthy tissues. Serum level of microRNA-218 was lower, while serum level of GLUT1 was higher in cancer patients than that in healthy control. Serum microRNA-218 and GLUT1 can be used to accurately predict OSCC and its prognosis. MicroRNA-218 knockdown promoted tumor cell proliferation, increased glucose uptake and promoted GLUT1 expression. CONCLUSIONS: Inhibition of microRNA-218 can promote oral cancer cell growth by targeting GLUT1 to affect glucose metabolism.
    [Abstract] [Full Text] [Related] [New Search]